Melanoma subsequent to natalizumab exposure: A report from the RADAR (Research on Adverse Drug events And Reports) program

J Am Acad Dermatol. 2019 Mar;80(3):820-821. doi: 10.1016/j.jaad.2018.10.052. Epub 2018 Nov 3.

Authors

Ryan C Kelm¹, Erika L Hagstrom¹, Regine J Mathieu¹, Kelsey A Orrell¹, Linda Serrano¹, Kelly A Mueller¹, Anne E Laumann¹, Dennis P West², Beatrice Nardone³

Affiliations

¹ Department of Dermatology, Northwestern University, Chicago, Illinois.
² Department of Dermatology, Northwestern University, Chicago, Illinois; Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois.
³ Department of Dermatology, Northwestern University, Chicago, Illinois. Electronic address: b-nardone@northwestern.edu.

PMID: 30395915
DOI: 10.1016/j.jaad.2018.10.052

No abstract available

Publication types

Letter

MeSH terms

Databases, Factual
Humans
Immunologic Factors / therapeutic use*
Melanoma / epidemiology*
Multiple Sclerosis / drug therapy*
Natalizumab / therapeutic use*
Skin Neoplasms / epidemiology*
United States / epidemiology

Substances

Immunologic Factors
Natalizumab